Loading...
Loading...
VBLT| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 2.0K |
| Operating Expense | 5,382.0K |
| Operating I/L | -5,380.0K |
| Other Income/Expense | 161.0K |
| Interest Income | 0.0K |
| Pretax | -5,219.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -5,219.0K |
Vascular Biogenics Ltd. is a clinical stage biopharmaceutical company specializing in the development of therapeutics for cancer and immune-inflammatory diseases. The company's primary focus is on its lead product candidate, VB-111, a gene-based biologic currently in Phase III clinical trials for recurrent platinum-resistant ovarian cancer, with additional Phase II trials for recurrent glioblastoma and colorectal cancer. Vascular Biogenics is also developing VB-601 for various inflammatory indications and VB-611 for various solid tumors. The company's revenue is generated through the development and potential commercialization of these innovative therapeutics targeting newly formed blood vessels and monocyte migration.
